BioMarin Pharmaceutical Inc.
BMRN · Nasdaq
BMRN · Nasdaq
BioMarin Pharmaceutical is a pharmaceutical and biotechnology company that develops and commercializes medicines. The supplied evidence does not identify its products, reporting segments, customer mix, geographic exposure, or the revenue contribution of individual businesses. It reports total revenue of $3.2 billion for FY2025, up from $2.9 billion in FY2024, and FY2025 net income of $0.3 billion versus $0.4 billion the prior year. On the available figures, BioMarin operates at multibillion-dollar annual revenue scale, but the evidence does not support a more detailed description of how revenue is divided among therapies or customer groups.
